Response to: Letter to the Editor From Fitzpatrick et al: "Zoledronate After Denosumab Discontinuation: Is Repeated Administrations More Effective Than Single Infusion?".
作者信息
Grassi Giorgia, Ghielmetti Alberto, Zampogna Marta, Chiodini Iacopo, Arosio Maura, Mantovani Giovanna, Eller-Vainicher Cristina
机构信息
Endocrine Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy.
Department of Clinical Sciences and Community Health, University of Milan, 20100 Milan, Italy.
出版信息
J Clin Endocrinol Metab. 2024 Nov 18;109(12):e2360-e2361. doi: 10.1210/clinem/dgae493.
PMID:39008610
Abstract
摘要
相似文献
1
Response to: Letter to the Editor From Fitzpatrick et al: "Zoledronate After Denosumab Discontinuation: Is Repeated Administrations More Effective Than Single Infusion?".对菲茨帕特里克等人致编辑的信的回复：“停用地诺单抗后使用唑来膦酸：重复给药比单次输注更有效吗？”
J Clin Endocrinol Metab. 2024 Nov 18;109(12):e2360-e2361. doi: 10.1210/clinem/dgae493.
2
Letter to the Editor From Fitzpatrick et al: "Zoledronate After Denosumab Discontinuation: Is Repeated Administrations More Effective Than A Single Infusion?".致编辑的信 来自菲茨帕特里克等人：“地诺单抗停药后使用唑来膦酸：重复给药比单次输注更有效吗？”
J Clin Endocrinol Metab. 2024 Nov 18;109(12):e2358-e2359. doi: 10.1210/clinem/dgae491.
3
Correction to: "Zoledronate After Denosumab Discontinuation: Is Repeated Administrations More Effective Than Single Infusion?".对《地诺单抗停药后唑来膦酸：重复给药比单次输注更有效吗？》的勘误
J Clin Endocrinol Metab. 2024 Sep 16;109(10):e1986. doi: 10.1210/clinem/dgae429.
4
Zoledronate After Denosumab Discontinuation: Is Repeated Administrations More Effective Than Single Infusion?地诺单抗停药后使用唑来膦酸：重复给药比单次输注更有效吗？
J Clin Endocrinol Metab. 2024 Sep 16;109(10):e1817-e1826. doi: 10.1210/clinem/dgae224.
5
A Single Infusion of Zoledronate in Postmenopausal Women Following Denosumab Discontinuation Results in Partial Conservation of Bone Mass Gains.唑来膦酸单次输注可部分保留绝经后妇女停用地舒单抗后的骨量获益。
J Bone Miner Res. 2020 Jul;35(7):1207-1215. doi: 10.1002/jbmr.3962. Epub 2020 Feb 11.
6
The three-year effect of a single zoledronate infusion on bone mineral density and bone turnover markers following denosumab discontinuation in women with postmenopausal osteoporosis.唑来膦酸单次输注对绝经后骨质疏松症女性停用地舒单抗后骨密度和骨转换标志物的三年影响。
Bone. 2020 Sep;138:115478. doi: 10.1016/j.bone.2020.115478. Epub 2020 Jun 11.
7
Bone Mass Gains After One Denosumab Injection Followed by Zoledronate.注射地舒单抗一次后接着用唑来膦酸治疗可增加骨量。
J Clin Densitom. 2022 Jul-Sep;25(3):293-298. doi: 10.1016/j.jocd.2022.03.001. Epub 2022 Mar 24.
8
The Five-Year Effect of a Single Zoledronate Infusion on Bone Mineral Density Following Denosumab Discontinuation in Women with Postmenopausal Osteoporosis.唑来膦酸单次输注对绝经后骨质疏松症女性停用地舒单抗后骨密度的 5 年影响。
Calcif Tissue Int. 2023 Oct;113(4):469-473. doi: 10.1007/s00223-023-01119-7. Epub 2023 Aug 3.
9
The Duration of Denosumab Treatment and the Efficacy of Zoledronate to Preserve Bone Mineral Density After Its Discontinuation.地舒单抗治疗持续时间和唑来膦酸在停药后维持骨密度的疗效。
J Clin Endocrinol Metab. 2021 Sep 27;106(10):e4155-e4162. doi: 10.1210/clinem/dgab321.
10
Comparative Effect of Zoledronate at 6 Versus 18 Months Following Denosumab Discontinuation.唑来膦酸在停用地舒单抗 6 个月与 18 个月后的比较疗效。
Calcif Tissue Int. 2021 May;108(5):587-594. doi: 10.1007/s00223-020-00785-1. Epub 2021 Jan 2.
Zotero 插件